Over the next 10 years, he built a research programme that bridged basic research and the clinical sciences. These included the RCSI Clinical Research Centre; the Institute for Biopharmaceutical Sciences; SurGen, a pharmacogenomics company; the RCSI Centre for Human Proteomics; Java Clinical Research, a spin-out CRO; the RCSI biobanking facility; and a bioinformatics programme that in partnership with Siemens designed the innovative ‘proteomics pipeline’.
